Eli Lilly will raise the UK list price of its weight-loss and type 2 diabetes treatment Mounjaro by up to 170% to be in line with other European markets, it said on Thursday, as the pharma industry responds to U.

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials. The weight loss pill also significantly improved heart health markers like cholesterol and blood pressure.

People paying privately for weight-loss drug Mounjaro in the UK face a rise in the cost of the treatment after manufacturer Eli Lilly said it was increasing the list price of the drug by as much as 170%.